Dupixent, the pioneering biologic, has shown remarkable success in reducing symptoms and achieving disease remission in a pivotal study on bullous pemphigoid.

Nxera Pharma's collaborator Centessa reveals encouraging interim Phase 1 clinical results for their new OX2R agonist, ORX750, in healthy volunteers with acute sleep deprivation.

The U.S. FDA has approved TREMFYA® (guselkumab) for adults with moderate to severe ulcerative colitis, bolstering Johnson & Johnson's position in the inflammatory bowel disease market.

Beijing QL Biopharmaceutical revealed Phase 1c clinical results for its primary drug candidate ZT002 at the EASD Annual Meeting 2024.

Cytokinetics, Incorporated (Nasdaq: CYTK) disclosed that data from the Phase 1 clinical trial of CK-4021586 (CK-586) were showcased during a poster presentation at the ACCP Annual Meeting.

CytomX Therapeutics reports initial patient treatment with CX-801, a dual-masked Interferon-Alpha 2b PROBODY®, in a Phase 1 trial for solid tumor patients.

Zealand Pharma reveals encouraging top-line outcomes from a 13-week Phase 1b trial of their GLP-1/GLP-2 receptor dual agonist dapiglutide.

Moleculin Reports Initial Patients Treated in Phase 2 Trial Combining STAT3 Inhibitor with Radiation for Glioblastoma Therapy.

Sep 14th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Boehringer's zongertinib demonstrates promising effectiveness and tolerability in patients with HER2-mutated lung cancer who have undergone prior treatment.

On September 11, 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of moderate to severe active ulcerative colitis (UC).

Phanes Therapeutics reported that the first patient has received a dose in the clinical trial of PT886 alongside chemotherapy.